Compass Therapeutics Inc Financials
This page shows Compass Therapeutics Inc (CMPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Compass Therapeutics Inc's revenue declined 100% year-over-year, from $850K to $0. This contraction results in a growth score of 0/100.
Compass Therapeutics Inc carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 15.02, Compass Therapeutics Inc holds $15.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Compass Therapeutics Inc generates a -33.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -39.4% the prior year.
Compass Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Compass Therapeutics Inc generates $0.74 in operating cash flow (-$49.1M OCF vs -$66.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Compass Therapeutics Inc generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Compass Therapeutics Inc's EBITDA was -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.5% from the prior year.
Compass Therapeutics Inc reported -$66.5M in net income in fiscal year 2025. This represents a decrease of 34.7% from the prior year.
Cash & Balance Sheet
Compass Therapeutics Inc generated -$49.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 9.5% from the prior year.
Compass Therapeutics Inc held $30.6M in cash against $0 in long-term debt as of fiscal year 2025.
Compass Therapeutics Inc had 178M shares outstanding in fiscal year 2025. This represents an increase of 29.4% from the prior year.
Margins & Returns
Compass Therapeutics Inc's ROE was -33.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.6 percentage points from the prior year.
Capital Allocation
Compass Therapeutics Inc invested $56.0M in research and development in fiscal year 2025. This represents an increase of 32.2% from the prior year.
Compass Therapeutics Inc invested $25K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 43.2% from the prior year.
CMPX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | N/A | N/A | $0-100.0% | $850K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $12.8M-21.9% | $16.4M+25.7% | $13.1M | N/A | $8.6M-22.9% | $11.2M+17.3% | $9.5M |
| SG&A Expenses | N/A | $3.0M-35.7% | $4.7M-5.3% | $4.9M | N/A | $3.6M-23.2% | $4.7M+45.4% | $3.2M |
| Operating Income | N/A | -$15.8M+24.9% | -$21.1M-17.3% | -$18.0M | N/A | -$12.2M+18.7% | -$15.0M-17.8% | -$12.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $0 | N/A | N/A | $0 | $0 |
| Net Income | N/A | -$14.3M+28.3% | -$19.9M-19.5% | -$16.6M | N/A | -$10.5M+19.8% | -$13.1M-21.2% | -$10.8M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CMPX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $219.6M-5.0% | $231.3M+98.2% | $116.7M-11.2% | $131.5M-6.4% | $140.4M-5.9% | $149.2M-4.2% | $155.6M-3.4% | $161.1M |
| Current Assets | $209.8M-5.1% | $221.1M+108.2% | $106.2M-14.5% | $124.1M-6.5% | $132.8M-5.9% | $141.1M-8.1% | $153.5M-3.2% | $158.6M |
| Cash & Equivalents | $30.6M-33.7% | $46.2M+102.2% | $22.9M-44.3% | $41.0M-5.6% | $43.5M+124.1% | $19.4M0.0% | $19.4M-55.4% | $43.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $22.8M+5.3% | $21.6M-7.9% | $23.5M+11.0% | $21.2M+39.6% | $15.2M+41.1% | $10.8M+13.1% | $9.5M+132.9% | $4.1M |
| Current Liabilities | $14.0M+12.5% | $12.4M-10.4% | $13.9M-7.0% | $14.9M+67.9% | $8.9M+100.2% | $4.4M-53.4% | $9.5M+144.2% | $3.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $196.8M-6.1% | $209.6M+124.9% | $93.2M-15.5% | $110.3M-11.9% | $125.2M-9.5% | $138.4M-5.3% | $146.1M-7.0% | $157.1M |
| Retained Earnings | -$431.2M-3.8% | -$415.5M-3.6% | -$401.2M-5.2% | -$381.3M-4.6% | -$364.7M-4.3% | -$349.7M-3.1% | -$339.2M-4.0% | -$326.1M |
CMPX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.3M-22.2% | -$10.8M+8.3% | -$11.8M+10.4% | -$13.2M-44.2% | -$9.2M+17.1% | -$11.1M-2.8% | -$10.8M+22.6% | -$13.9M |
| Capital Expenditures | $0-100.0% | $7K | $0-100.0% | $18K | $0-100.0% | $44K | $0 | $0 |
| Free Cash Flow | -$13.3M-22.1% | -$10.9M+8.2% | -$11.8M+10.5% | -$13.2M-44.4% | -$9.2M+17.4% | -$11.1M-3.2% | -$10.8M+22.6% | -$13.9M |
| Investing Cash Flow | -$3.4M+96.5% | -$95.2M-1396.2% | -$6.4M-154.9% | $11.6M-24.6% | $15.4M-47.0% | $29.0M+347.6% | $6.5M+258.2% | -$4.1M |
| Financing Cash Flow | $1.1M-99.2% | $129.4M | $0+100.0% | -$815K-767.0% | -$94K-4600.0% | -$2K-300.0% | $1K-100.0% | $17.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CMPX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1770.0% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1538.3% | N/A |
| Return on Equity | N/A | -6.8%+14.5pp | -21.3%-6.3pp | -15.1% | N/A | -7.6%+1.4pp | -8.9%-2.1pp | -6.9% |
| Return on Assets | N/A | -6.2%+10.9pp | -17.0%-4.4pp | -12.7% | N/A | -7.0%+1.4pp | -8.4%-1.7pp | -6.7% |
| Current Ratio | 15.02-2.8 | 17.82+10.2 | 7.66-0.7 | 8.33-6.6 | 14.96-16.9 | 31.84+15.7 | 16.15-24.6 | 40.74 |
| Debt-to-Equity | 0.12+0.0 | 0.10-0.1 | 0.25+0.1 | 0.19+0.1 | 0.12+0.0 | 0.08+0.0 | 0.07+0.0 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1265.2% | N/A |
Similar Companies
Frequently Asked Questions
What is Compass Therapeutics Inc's annual revenue?
Compass Therapeutics Inc (CMPX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Compass Therapeutics Inc's revenue growing?
Compass Therapeutics Inc (CMPX) revenue declined by 100% year-over-year, from $850K to $0 in fiscal year 2025.
Is Compass Therapeutics Inc profitable?
No, Compass Therapeutics Inc (CMPX) reported a net income of -$66.5M in fiscal year 2025.
What is Compass Therapeutics Inc's EBITDA?
Compass Therapeutics Inc (CMPX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Compass Therapeutics Inc's return on equity (ROE)?
Compass Therapeutics Inc (CMPX) has a return on equity of -33.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Compass Therapeutics Inc's free cash flow?
Compass Therapeutics Inc (CMPX) generated -$49.2M in free cash flow during fiscal year 2025. This represents a -9.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Compass Therapeutics Inc's operating cash flow?
Compass Therapeutics Inc (CMPX) generated -$49.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Compass Therapeutics Inc's total assets?
Compass Therapeutics Inc (CMPX) had $219.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Compass Therapeutics Inc's capital expenditures?
Compass Therapeutics Inc (CMPX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Compass Therapeutics Inc spend on research and development?
Compass Therapeutics Inc (CMPX) invested $56.0M in research and development during fiscal year 2025.
What is Compass Therapeutics Inc's current ratio?
Compass Therapeutics Inc (CMPX) had a current ratio of 15.02 as of fiscal year 2025, which is generally considered healthy.
What is Compass Therapeutics Inc's debt-to-equity ratio?
Compass Therapeutics Inc (CMPX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Compass Therapeutics Inc's return on assets (ROA)?
Compass Therapeutics Inc (CMPX) had a return on assets of -30.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Compass Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Compass Therapeutics Inc (CMPX) had $30.6M in cash against an annual operating cash burn of $49.1M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Compass Therapeutics Inc's Piotroski F-Score?
Compass Therapeutics Inc (CMPX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Compass Therapeutics Inc's earnings high quality?
Compass Therapeutics Inc (CMPX) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Compass Therapeutics Inc?
Compass Therapeutics Inc (CMPX) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.